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Impairments in executive functions are frequently reported in Parkinson’s disease (PD). However, little is
known about patients’ experience regarding these impairments. This knowledge is crucial because if
patients do not experience their cognitive impairments they do not report them to their attending
neurologist. Consequently, patients might not get appropriate treatment. This study investigated if
patients with a mild to moderate PD experience impairments in executive functions in daily life and
whether these correspond with impairments as measured in neuropsychological assessments.
Forty-three PD patients and 25 healthy participants were included. Groups did not differ in age, sex
and education. All participants and their closest relatives completed a standardized questionnaire
measuring executive functions in daily life. Furthermore, all participants were assessed with a test
battery measuring executive functions.
PD patients reported signiﬁcantly more problems with executive functions in daily life than healthy
participants. Furthermore, co-morbid depression had a negative impact on the number of problems with
executive functions in daily life as reported by PD patients. The experienced daily life problems in
executive functions were not associated with the patients’ performance on objective cognitive measures.
In conclusion, PD patients were aware of problems with executive functions in daily life and reported
considerably more problems than healthy controls. These problems were however not reﬂected by
neuropsychological tests and may indicate a lack of ecological validity of neuropsychological assessment.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
An important issue in the assessment of neurological patients is
the accuracy with which patients can rate the cognitive impair-
ments they encounter in daily life. A problem that often occurs,
however, is that not all patients with cognitive impairments
complain about their cognitive limitations [1,2]. To overcome this
problem, neuropsychological assessment procedures are used.
However, the standard tests used in these assessments do not
always reﬂect daily life cognitive impairments [3,4].
Parkinson’s disease (PD) is a neurological disorder in which
cognitive impairments are apparent, in particular in the domain of
executive functions [5], and only little is known about to whatd Developmental Neuropsy-
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sevier OA license.extent patients experience their cognitive limitations. The few
studies that focused on the complaints of PD patients with regard to
their cognitive impairments are characterized by methodological
limitations (e.g. lack of concurrent validity of test measures
applied) and inconsistent results [6e8]. Since complaints about
cognitive limitations have a negative impact on caregivers’ stress
and inﬂuence the willingness of patients to seek or to comply with
treatment [9,10], knowledge about PD patients’ experience of
cognitive limitations appears crucial. In addition, it is important to
determine whether manifestations of cognitive limitations in daily
life as reported by PD patients correspond with impairments found
in neuropsychological assessments. This knowledge might provide
an insight in the accuracy of patients’ self-reports but also in the
ecological validity of neuropsychological tests. The current study
aimed to determine if patients with a mild to moderate PD expe-
rience impairments in executive functions in daily life and whether
these are associated with both evaluations of relatives and the
results of neuropsychological measurements.
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2.1. Participants
Forty-three PD patients participated in this study. All patients were recruited
from the Movement Disorders outpatient clinic of the Department of Neurology of
the University Medical Center Groningen (UMCG), The Netherlands, and were
diagnosed with idiopathic PD according to the criteria of the UK Parkinson’s Disease
Society Brain Bank. The motor severity of symptoms was assessed with the Uniﬁed
Parkinson’s Disease Rating Scale and Hoehn and Yahr scale (H&Y). A Levodopa
Equivalent Daily Dose (LEDD) was calculated for all patients [11]. All patients were
assessed in their regular on-state of medication. In addition, 25 healthy participants
were included in this study. Level of education was rated for all participants with
a Dutch education scale, ranging from 1 (elementary school not ﬁnished) to 7
(university degree). Groups did not differ in age (t ¼ 0.35; p ¼ not signiﬁcant; ns),
gender (Chi-Square ¼ 0.88; p ¼ ns) and education level (Z ¼ 1.58; p ¼ ns).
Descriptive and disease characteristics of PD patients and healthy participants are
reported in Table 1. Patients with dementia (MMSE< 24) and neurological disorders
other than PD were excluded. This study was approved by the medical ethical
committee of the UMCG. All participants signed an informed consent prior to study
inclusion.
2.2. Stimulus material
2.2.1. Executive functions in daily life
The Dysexecutive questionnaire (DEX) [12] is a sensitive instrument with an
adequate concurrent validity [13]. It consists of 20 questions that cover the most
commonly reported symptoms of the dysexecutive syndrome. Participants are asked
to rate on a scale that ranges from 0 (never) to 4 (very often) how often they
observed the symptoms described in the DEX (DEX self). Furthermore, a close rela-
tive of the participant was also asked to complete the DEX and to rate howoften they
observed the symptoms of the dysexecutive syndrome in their relative (DEX other).
For both the DEX self and the DEX other a total score was calculated.
2.2.2. Neuropsychological test measures of executive functions
Several standardized, reliable and valid neuropsychological test measures of
executive functions were applied in this study [14]. The Stroop Color Word Test [15]
was used to measure inhibition. Cognitive ﬂexibility was assessed with the Trail
Making Test [16] and the Odd Man Out [17]. The Digit Span of the Wechsler Memory
ScaleeRevised [18] was used to assess working memory. Semantic and phonemic
verbal ﬂuency testswere used to evaluate divergent thinking. Finally, the Zoo-Map of
the Behavioral Assessment of the Dysexecutive Syndrome [19] was used to assess
planning.
2.3. Statistical analyses
Normality of data was analyzed, using the ShapiroeWilk test and QQ-plots.
While the DEX self and DEX other were normally distributed, neuropsychological
testmeasures of executive functions were not. Therefore, parametric tests were used
when comparing the performance of groups on the DEX self and DEX other. Non-
parametric tests were used when comparing the test performances of groups or
when calculating associations between test performances and the DEX self and DEX
other.
T-tests for independent samples were used to compare the performance of PD
patients and healthy participants on the DEX self and DEX other. The ManneWithneyTable 1
Descriptive and disease characteristics of PD patients (n ¼ 43) and healthy partici-
pants (n ¼ 25).
PD patients Healthy participants
M (SD) M (SD)
Age (years) 63.7 (8.6) 62.8 (11.5)
Educationa 5.2 (1.1) 4.8 (0.7)
Gender
Male: n (%) 24 (56) 11 (44)
Female: n (%) 19 (44) 14 (56)
MADRS total 9.2 (7.1) 2.3 (2.1)
MMSE total 27.5 (1.4) 27.6 (1.2)
Disease duration (years) 5.1 (4.1)
UPDRS, part III 24.6 (8.8)
H&Y 2.2 (0.6)
LEDD 561.7 (435.3)
MADRS¼Montgomery-Åsberg Depression Rating Scale; MMSE¼Mini Mental State
Examination; UPDRS ¼ Uniﬁed Parkinson’s Disease Rating Scale; H&Y ¼ Hoehn and
Yahr scale; LEDD ¼ Levodopa Equivalent Daily Dose.
a Dutch education scale ranging from 1 (elementary school not ﬁnished) to 7
(university degree).U test was used to compare the performance of groups on tests of executive func-
tions. To determine the associations between the scores on the DEX self, DEX other
and test performances, Spearman correlations were calculated. Furthermore, to
determine whether the rating of participants corresponded with the rating of their
relatives, the scores on the DEX selfwere compared with the scores on the DEX other
within each group using related samples t-test.
Besides comparing PD patients to healthy participants, the rating of PD patients
in H&Y stage 1e2 on the DEX self and DEX other were compared to PD patients in
H&Y stage 2.5e3. PD patients in H&Y stage 2.5e3 had a signiﬁcantly higher age
(t¼3.0; p¼ 0.005) and a signiﬁcantly lower level of education (z¼2.4; p¼ 0.02)
than PD patients in H&Y stage 1e2. Both groups were comparable with regard to
gender (Chi-Square ¼ 3.6; p ¼ ns). Therefore, a MANCOVAwas used to compare the
ratings on the DEX self and DEX other of PD patients in H&Y stage 1e2 and PD
patients in H&Y stage 2.5e3, including age and education as covariates. Also, within
these groups the DEX self was compared to the DEX other using related samples t-
tests. Since a (M)ANCOVA is robust against deviations from normality [20], this test
was also used for comparison of test performance between PD patients in H&Y stage
1e2 and PD patients in H&Y stage 2.5e3 with age and education as covariates. All
these calculations were also performed with the groups of PD patients with co-
morbid depression (MADRS score  18; [21]) and PD patients without depression
(MADRS score < 18; [21]). However, since PD patients with co-morbid depression
and PD patients without depression did not differ regarding age (t ¼ 1.1; p ¼ ns),
education (z ¼ 1.0; p ¼ ns) and gender (Chi-Square ¼ 0.1; p ¼ ns) t-tests and
ManneWithney U tests were used for data analyses. Finally, Cohen’s d was calcu-
lated for all comparisons. The threshold for statistical signiﬁcance was 0.05.
3. Results
3.1. Comparison of PD patients and healthy participants
PD patients showed signiﬁcantly higher scores on the DEX self
compared to healthy participants (t ¼ 2.1; p ¼ 0.04; d ¼ 0.5). No
differences were found between these groups for the DEX other
(t ¼ 1.9; p ¼ ns; d ¼ 0.4; Fig. 1a). In PD patients, 58% of ‘relatives’
were partners, 19% children, 12% close friends or family members. In
11% of cases the type of relationship was unknown. All ‘relatives’
were caregivers of patients. In the group of healthy participants, 44%
of the ‘relatives’ were partners,12% children and 28% close friends or
family members. In 16% of cases the type of relationship was
unknown. PD patients and healthy participants reported on average
the same number of problems as their relatives (respectively,
t ¼ 1.6; p ¼ ns; d ¼ 0.2 and t ¼ 1.6; p ¼ ns; d ¼ 0.5; Fig. 1a). PD
patients also showed signiﬁcantly lower scores on tests of executive
functions than healthy participants (Table 2). However, only weak
non-signiﬁcant associations were found between the DEX self, DEX
other and the test performances of PD patients (correlations ranging
from respectively 0.13 to 0.18, and from 0.17 to 0.13).
3.2. Comparison of PD patients in H&Y stage 1e2 and PD patients
in H&Y stage 2.5e3
The DEX scores of patients in H&Y stage 1e2 were compared to
the scores of patients in H&Y stage 2.5e3, with a correction for age
and education. No differences were found between these groups
with regard to DEX self (F ¼ 1.9; p ¼ ns; d ¼ 0.4) and DEX other
(F ¼ 0.91; p ¼ ns; d ¼ 0.2; Fig. 1b). However, the DEX self differed
signiﬁcantly from the DEX other within PD patients in H&Y stage
2.5e3 (t ¼ 3.6; p ¼ 0.002; d ¼ 0.6). This difference was not found
within PD patients in H&Y stage 1e2 (t ¼ 0.3; p ¼ ns; d ¼ 0.1;
Fig. 1b). In neuropsychological assessment, no signiﬁcant differ-
ences were found between the two groups (F-scores ranging from
0.01 to 0.89; p-values ranging from 0.35 to 0.98; data not shown).
3.3. Comparison of PD patients with co-morbid depression and PD
patients without depression
PD patients with depression scored signiﬁcantly higher on the
DEX self (t ¼ 3.4; p ¼ 0.001; d ¼ 1.4) and DEX other (t ¼ 2.3;
p ¼ 0.02; d ¼ 0.9) compared to PD patients without depression
Table 2
Performance of PD patients (n ¼ 43) and healthy participants (n ¼ 25) on tests for
executive functions (two-tailed).
PD patients Healthy participants z p
M (SD) M (SD)
Inhibition
Stroop interference index 1.7 (0.4) 1.6 (0.2) 1.2 ns
Cognitive ﬂexibility
TMT B 126.0 (57.3) 102.6 (68.4) 2.5 0.01**
OMO no errors 5.4 (5.9) 1.2 (1.4) 3.5 <0.001**
Word ﬂuency
Fluency animals 21.1 (5.2) 21.6 (4.4) 0.5 ns
Fluency professions 15.2 (4.2) 17.5 (3.8) 2.2 0.03*
Fluency letters 38.3 (15.4) 38.7 (10.5) 0.6 ns
Working memory
WAIS digit span backwards 5.7 (2.1) 6.1 (1.4) 1.3 ns
Planning
Zoo map 2.4 (1.2) 2.8 (0.9) 1.4 ns
*p  0.05; **p  0.01.
TMT ¼ Trail Making Test; OMO ¼ Odd Man Out test; WAIS ¼ Wechsler Adult
Intelligence Scale; ns ¼ not signiﬁcant.
Fig. 1. Dysexecutive questionnaire (DEX): a. Scores of PD patients (n ¼ 45) and healthy
participants (n ¼ 25) on the DEX (Mean  SD), *p < 0.05. b. Scores of PD patients in
different stages of the disease on the DEX (Mean  SD; HY1-2 n ¼ 25; HY 2.5e3
n ¼ 18), *p < 0.05. c. DEX scores of PD patients with (n ¼ 8) and without depression
(n ¼ 35; Mean  SD), *p < 0.05.
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reported on average the same number of problems as their relatives
(respectively, t ¼ 1.1; p ¼ ns; d ¼ 0.5; t ¼ 1.5; p ¼ ns; d ¼ 0.2). PD
patients with depression did, however, not differ in tests measuring
executive functions from PD patients without depression (z-scores
ranging from0.4 to0.7; p-values ranging from 0.50 to 0.97; data
not shown).
4. Discussion
PD patients reported signiﬁcantly more problems with execu-
tive functions in daily life than healthy participants. Furthermore,there was agreement between PD patients and their relatives with
regard to the problems patients encounter in daily life, which
suggests that PD patients have a good insight into their daily life
functioning. This is the ﬁrst study to report that PD patients are
aware of impairments in executive functions in daily life and
experience more problems than healthy elderly people. These
results are in line with studies reporting that PD patients and their
relatives are aware of several other non-motor symptoms [22].
The problemswith executive functions indaily life reportedbyPD
patients did, however, not correspond with the neuropsychological
assessment, even though PD patients showed an impaired perfor-
mance on several tests of executive functions compared to healthy
participants. Three possible explanations should be considered. First,
neuropsychological tests do not always reﬂect executive impair-
ments patients encounter in daily life (i.e. low ecological validity)
[23]. This is possibly due to the fact that (classic) tests are usually very
structured (rules and goals are set and start and end of behavior are
prompted) [24e26]. However, situations in daily life are usually very
unstructured, oftenwithout a clearly deﬁned goal, solution, start and
end. Furthermore, various approaches might be possible to solve
a problem indaily life (e.g. planninga journey),while in standardized
test procedures there is usually only one correct approach. Limita-
tions in ecological validity of neuropsychological tests may thus
account for the lack of an association between theproblems reported
by patients and neuropsychological assessment. Second, other tests
(e.g. the CANTAB [27]) which are available to assess executive func-
tionsmight bebetter related to day to dayexecutive functions. Aﬁnal
explanation is that the DEX may not directly assess problems with
executive functions in daily life but reﬂects the negative affect that
accompanies the daily life problems with executive functions [28].
This latter explanation is consistent with the ﬁnding that depressed
PD patients reported signiﬁcant more problems with executive
functions in daily life than non-depressed PD patients, even though
no differences were found between these groups with regard to
neuropsychological assessment. The inﬂuence of a negativemoodon
the subjective perception of cognitive impairments has previously
been reported in PD [7] and in other neurological disorders [29,30]. A
negative mood might thus adversely affect the rating of items of the
DEX.
The agreement between PD patients and their relatives was,
however, not the same in patients at different stages of the disease.
Patients with mild PD reported on average the same number of
problems with executive functions in daily life than their relatives.
Patients with a moderate PD, on the other hand, reported on
average more problems with executive functions in daily life than
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the one hand, relatives of patients with moderate PD might not be
fully aware of the daily life problems with executive functions
patients might experience and may therefore underestimate these
problems. Since patients with a moderate PD often have a relatively
long disease duration, it is possible that their relatives became less
sensitive over time and consequently report those problems less
frequently. This is supported by the fact that patients with
moderate PD did on average not report more problems than
patients with mild PD. On the other hand, patients with moderate
PD may overestimate problems with executive functions in daily
life. Although it is possible that the insight of patients with
a moderate PD into their daily life functioning is decreased it
appears unlikely that this would result in an overestimation of
problems. Research demonstrated that patients with frontal lobe
pathology or neurodegenerative diseases are often indifferent to
the consequences of their condition and therefore more likely to
underestimate daily life problems [1].
A limitation of this study is the relative small group of PD
patients with depression. However, even in this small group
a signiﬁcant difference was found between PD patients with and
without depression in the number of problems with executive
functions in daily life. Another limitation of this study is that no
correction for multiple comparisons was performed. Important
ﬁndings would have been lost because of the adjustment of the p-
value. In this context, it has to be considered that the signiﬁcant
differences of the study are largely consistent with effect sizes,
which were of medium to large size. Nevertheless, this is a weak-
ness of the present study. In this context, the power of the study
also has to be considered. Because of the sample sizes the power of
analyses to detect a medium effect varied between 35% (e.g.
patients with depression versus patients without depression) and
62% (e.g. PD patients versus healthy participants). Therefore, the
results of some analyses should be viewed with caution. In future
studies the ﬁndings of this study should be replicated.
In conclusion, PD patients are aware of their problems with
executive functions in daily life and report considerably more
problems than healthy controls. The problems patients experience
in daily life did, however, not correspond with the results of neu-
ropsychological assessment. These ﬁndings indicate that standard
neuropsychological tests do not reﬂect the problems patients
encounter in their everyday life and underline the need of
ecologically valid neuropsychological tests. Finally, the present
study indicates that a depressed mood has a detrimental effect on
patients’ self evaluations of executive functions in daily life.
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